UBS Group
FLNA

UBS Group’s Filana Therapeutics FLNA Stock Holding History

UBS Group’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$19.6K Sell
11,603
-18,266
-61% -$37.6K ﹤0.01% 7949
2025
Q4 		$59.1K Sell
29,869
-159,124
-84% -$509K ﹤0.01% 7138
2025
Q3 		$550K Sell
188,993
-1,092
-0.6% -$2.51K ﹤0.01% 6026
2025
Q2 		$344K Sell
190,085
-355,730
-65% -$633K ﹤0.01% 6329
2025
Q1 		$819K Sell
545,815
-384,911
-41% -$971K ﹤0.01% 5457
2024
Q4 		$2.2M Buy
930,726
+841,853
+947% +$14.8M ﹤0.01% 4641
2024
Q3 		$2.62M Buy
88,873
+25,860
+41% +$596K ﹤0.01% 3734
2024
Q2 		$778K Sell
63,013
-21,713
-26% -$458K ﹤0.01% 4648
2024
Q1 		$1.72M Buy
84,726
+890
+1% +$20.5K ﹤0.01% 4089
2023
Q4 		$1.89M Buy
83,836
+56,170
+203% +$1.19M ﹤0.01% 3880
2023
Q3 		$460K Sell
27,666
-36,132
-57% -$716K ﹤0.01% 4724
2023
Q2 		$1.56M Buy
63,798
+5,594
+10% +$135K ﹤0.01% 3779
2023
Q1 		$1.4M Buy
58,204
+16,556
+40% +$459K ﹤0.01% 3793
2022
Q4 		$1.23M Buy
41,648
+11,001
+36% +$395K ﹤0.01% 3877
2022
Q3 		$1.28M Buy
30,647
+25,685
+518% +$694K ﹤0.01% 3536
2022
Q2 		$140K Sell
4,962
-1,323
-21% -$33.4K ﹤0.01% 5177
2022
Q1 		$233K Sell
6,285
-1,451
-19% -$61.5K ﹤0.01% 5239
2021
Q4 		$338K Buy
7,736
+825
+12% +$43.3K ﹤0.01% 5286
2021
Q3 		$429K Buy
6,911
+2,834
+70% +$237K ﹤0.01% 4831
2021
Q2 		$348K Sell
4,077
-562
-12% -$30.1K ﹤0.01% 4978
2021
Q1 		$209K Sell
4,639
-2,681
-37% -$105K ﹤0.01% 5453
2020
Q4 		$49K Buy
7,320
+6,879
+1,560% +$61.4K ﹤0.01% 6206
2020
Q3 		$5K Sell
441
-9,304
-95% -$41.9K ﹤0.01% 7332
2020
Q2 		$30K Sell
9,745
-290,545
-97% -$1.32M ﹤0.01% 6277
2020
Q1 		$1.23M Buy
300,290
+297,583
+10,993% +$1.97M ﹤0.01% 3171
2019
Q4 		$14K Buy
2,707
+2,417
+833% +$4.17K ﹤0.01% 7097
2019
Q3 		$0 Sell
290
-3,466
-92% -$4.45K ﹤0.01% 8219
2019
Q2 		$5K Buy
3,756
+608
+19% +$690 ﹤0.01% 7388
2019
Q1 		$4K Sell
3,148
-7,931
-72% -$9.1K ﹤0.01% 7268
2018
Q4 		$10K Buy
11,079
+4,931
+80% +$5.67K ﹤0.01% 7241
2018
Q3 		$6K Sell
6,148
-1,345
-18% -$2.04K ﹤0.01% 7412
2018
Q2 		$16K Buy
7,493
+3,506
+88% +$30.1K ﹤0.01% 6852
2018
Q1 		$28K Sell
3,987
-11,432
-74% -$77.2K ﹤0.01% 6155
2017
Q4 		$62K Buy
15,419
+15,180
+6,351% +$61.3K ﹤0.01% 5684
2017
Q3 		$1K Sell
239
-3,574
-94% -$12.8K ﹤0.01% 7588
2017
Q2 		$16K Buy
3,813
+3,684
+2,856% +$17.4K ﹤0.01% 6461
2017
Q1 		$1K Sell
129
-11,873
-99% -$53.9K ﹤0.01% 7453
2016
Q4 		$48K Buy
12,002
+11,873
+9,204% +$55.1K ﹤0.01% 5867
2016
Q3 		$1K Hold
129
– – ﹤0.01% 7541
2016
Q2 		$2K Hold
129
– – ﹤0.01% 7444
2016
Q1 		$2K Sell
129
-371
-74% -$4.8K ﹤0.01% 7325
2015
Q4 		$7K Buy
500
+371
+288% +$4.91K ﹤0.01% 7527
2015
Q3 		$2K Hold
129
– – ﹤0.01% 8096
2015
Q2 		$2K Sell
129
-160
-55% -$2.19K ﹤0.01% 8210
2015
Q1 		$4K Sell
289
-212
-42% -$2.86K ﹤0.01% 8233
2014
Q4 		$7K Buy
+501
New +$8.67K ﹤0.01% 8715

Other funds holding FLNA

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Group One Trading
Group One Trading Chicago, Illinois $52.2B AUM 104.56% 1-Year Est. Return

UBS Group's FLNA Position: Q1 2026 in Review

UBS Group reduced its Filana Therapeutics (FLNA) stake by 61% in Q1 2026, selling an estimated $37.6K and leaving 11,603 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #7949.

UBS Group first reported a position in FLNA in Q4 2014 and has held it in 46 quarters since. The position peaked at $2.62M in Q3 2024. 101 funds tracked by Wall St. Rank hold FLNA as of Q1 2026.

  • UBS Group held 11,603 shares of Filana Therapeutics worth $19.6K as of Q1 2026.
  • UBS Group sold 18,266 Filana Therapeutics shares in Q1 2026, an estimated $37.6K.
  • Filana Therapeutics made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #7949 holding.
  • UBS Group first reported a position in Filana Therapeutics in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Filana Therapeutics position peaked at $2.62M in Q3 2024.
  • 101 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.